Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

2025 ARTÍCULOS , VIENDO DEL 421 AL 435

Targeting Metabolic Dysregulation in Alzheimer's Disease: A Potential Therapeutic Strategy

Barnwal N, Dubey S, Tiwari P.

Curr Drug Metab. 2025;26(7):455-471. doi: 10.2174/0113892002408089250912080734.

Exercise as a Therapeutic Intervention for Alzheimer's Disease

Hwang DJ, Cho JY.

Adv Neurobiol. 2025;44:297-316. doi: 10.1007/978-981-95-0066-6_16.

Perspectives on Alzheimer's Disease Treatment Based on Counteracting Oxidative Stress

Bilski R, Dąbkowski S, Kozieł I, Kozicki M, Małachowska A, Przygocki M, Tyska O.

Biomolecules. 2025 Sep 19;15(9):1345. doi: 10.3390/biom15091345.

Boosting Neurogenesis as a Strategy in Treating Alzheimer's Disease

Dwamena A, Beragama-Arachchi R, Wang H.

Int J Mol Sci. 2025 Sep 13;26(18):8926. doi: 10.3390/ijms26188926.

Chimeric Antigen Receptor Cell Therapy: Current Status and Its Potential in Aging and Alzheimer's Disease

Jurcau MC, Iovanovici CD, Jurcau A, Militaru M, Udrea RB, Comanescu A, Nunkoo VS.

Int J Mol Sci. 2025 Sep 16;26(18):9009. doi: 10.3390/ijms26189009.

The involvement of HIF-1α-dependent paracrine factors in Alzheimer's disease

Zhdankina VI, Perepelitsa ES, Blagova AV, Komleva YK, Baranich TI, Salmina AB.

Rev Neurosci. 2025 Oct 7;37(1):61-75. doi: 10.1515/revneuro-2025-0102. Print 2026 Jan 23.

[Disease-modifying therapy with lecanemab for early Alzheimer's dementia]

Hansen N, Wiltfang J.

Fortschr Neurol Psychiatr. 2025 Nov;93(11):453-460. doi: 10.1055/a-2681-4558. Epub 2025 Oct 6.

Astrocyte response in Alzheimer's disease: Good or bad?

Ismail A, Al-Kuraishy HM, Al-Gareeb AI, Albuhadily AK, Yassen ASA, Alexiou A, Papadakis M, Batiha GE.

Brain Res. 2025 Dec 1;1868:149971. doi: 10.1016/j.brainres.2025.149971. Epub 2025 Oct 6.

The rhythm of decline: Circadian disruption in neurodegeneration

Singh J, Kumar D, Kaur J, Singh A.

J Food Drug Anal. 2025 Sep 18;33(3):224-240. doi: 10.38212/2224-6614.3553.

Brain somatic mutations in Alzheimer's disease: linking genetic mosaicism to neurodegeneration

Li Z, Zhang J, Liu Z, Yu L, Yang C, Zhang L, Xiang Z, Hu F, Brazh N, Shu K, Zhu LQ, Liu D.

Mol Neurodegener. 2025 Oct 9;20(1):104. doi: 10.1186/s13024-025-00895-0.

Photothermal nano-agents: an innovative trident weapon for accurate and effective treatment of alzheimer's disease

Chen J, Zhang X, Sun J, Zhi Y, Xie Z, Guan Y, Zhang Z, Wu C.

J Nanobiotechnology. 2025 Oct 10;23(1):650. doi: 10.1186/s12951-025-03709-z.

Tau-Targeted Therapeutic Strategies: Mechanistic Targets, Clinical Pipelines, and Analysis of Failures

Shen X, Li H, Zhang B, Li Y, Zhu Z.

Cells. 2025 Sep 26;14(19):1506. doi: 10.3390/cells14191506.

Targeting Oligodendrocyte Dysfunction in Alzheimer's Disease: a New Frontier for Drug Repurposing with Antihistamines and Serotonin Receptor Agonists

Gurikar S, Ahmed SS, Raghunatahanaidu BD.

J Mol Neurosci. 2025 Oct 15;75(4):139. doi: 10.1007/s12031-025-02433-5.

Gene-Exercise Interactions in Amyloid Metabolism and Clearance: Implications for Alzheimer's Disease

Astorino MF, Cipriano GL, Anchesi I, Lui M, Raffaele I, Calabrò M, Crisafulli C.

Int J Mol Sci. 2025 Oct 9;26(19):9816. doi: 10.3390/ijms26199816.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias